Requires drug middlemen to disclose ownership and activities

File S00438 ("Requires drug middlemen to disclose ownership and activities") is before the New York Legislature and has not been decided. Latest step (February 25, 2026): AMENDED ON THIRD READING 438A.

New York file S00438, before the New York Legislature. Still to be decided as of 2026-02-25.

What it does

You may see clearer drug pricing through your pharmacy Pharmacy benefit managers and related middlemen must register and disclose their ownership and operations to state insurance regulators, potentially making it easier for you to understand why your prescriptions cost what they do.

The bigger picture

May lower drug costs by reducing hidden supply chain markups Requiring transparency of rebates, ownership structures, and switching activities could reduce opaque markups by middlemen and shift more negotiating power back to pharmacies and insurers.

What to watch

Disclosure requirements alone don't guarantee lower prices Transparency is a precondition for competition but does not mandate price reductions or limit what middlemen can charge; real savings depend on whether regulators and insurers act on disclosed information.

How they voted

Yes (54)

No (2)

Did not vote / other (7)

Read the official record for S00438

See everything up for a vote · This week in New York · See what we have filed with the clerk